A continuous association between albuminuria and cardiorenal risk exists further below moderately increased albuminuria ranges. If only based in albumin to creatinine ratio (ACR) higher than 30 mg/g, a significant percentage of individuals may be out of the scope for therapeutic management. Despite epidemiological outcomes, the identification of biochemical changes linked to early albuminuria is underexplored, and normoalbuminuric individuals are usually considered at no risk in clinical practice. Here, we aimed to identify early molecular alterations behind albuminuria development.

中文翻译：

---

在白蛋白尿正常的情况下出现早期肾脏和血管损伤。

蛋白尿与心肾风险之间存在持续关联，进一步低于蛋白尿适度升高的范围。如果仅基于白蛋白与肌酐比 (ACR) 高于 30 mg/g，很大一部分人可能超出治疗管理范围。尽管有流行病学结果，但与早期白蛋白尿相关的生化变化的识别尚未得到充分探索，并且在临床实践中通常认为白蛋白尿正常的个体没有风险。在这里，我们的目的是确定蛋白尿发展背后的早期分子改变。